Oscar Health (OSCR) Q2 Revenue Rises 29%

Oscar Health reported Q2 2025 revenue of $2.86 billion, a 29.0% year-over-year increase driven by strong membership growth, though it missed GAAP estimates. The company swung to a significant GAAP net loss of $228.4 million, primarily due to a sharp rise in its medical loss ratio to 91.1%, reflecting increased claims costs and unfavorable risk adjustment. Despite these operational setbacks and higher risk adjustment costs, management reaffirmed its full-year 2025 guidance, anticipating market stabilization and a return to profitability by 2026, underscoring ongoing profitability challenges within the volatile Affordable Care Act health plan market.

Analysis

Oscar Health's Q2 2025 results present a conflicting narrative of strong top-line expansion undermined by severe operational and profitability setbacks. Revenue grew 29% year-over-year to $2.86 billion, fueled by a 28% increase in total membership, yet this figure missed GAAP estimates by $54.7 million. The core issue was a dramatic deterioration in underwriting profitability, as the Medical Loss Ratio (MLR) surged to 91.1% from 79.0% a year prior. Management attributed this spike to higher market-wide morbidity and an unfavorable net risk adjustment transfer, indicating broad pressures within the ACA marketplace. This drove a significant swing to a GAAP net loss of $228.4 million, compared to a $56.2 million profit in Q2 2024, with Adjusted EBITDA also reversing to a loss of $199.4 million. While the company demonstrated some cost control with a reduced SG&A expense ratio of 18.7%, this was insufficient to offset the claims pressure. The rapid contraction of the Cigna+Oscar partnership further concentrates the business in the volatile individual market. Despite these headwinds, management reaffirmed its full-year 2025 guidance and forecasted a return to profitability in 2026, contingent on market stabilization.

Key Decisions for Investors

• Investors must weigh the strong 29% revenue growth against the severe deterioration in profitability, as the 91.1% Medical Loss Ratio presents a significant near-term risk to the company's financial health.
• Closely monitor the MLR and any management commentary on risk adjustment in the coming quarters, as a failure to bring these costs under control would directly threaten the reaffirmed full-year guidance and the projected 2026 return to profitability.
• Recognize the increased concentration risk in the volatile individual and small group ACA market following the effective wind-down of the Cigna+Oscar partnership.
• Given the significant earnings miss and swing to a loss, it may be prudent to await tangible evidence of stabilizing claims costs before initiating or adding to positions, as the path to management's 2026 profitability target appears highly challenging.